Acute porphyria: Treatment with heme

Seminars in Liver Disease

Volumn 18, Issue 1, 1998, Pages 53-55

  Tenhunen, Raimo ^a,b   Mustajoki, Pertti ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Heme; Porphyria

Indexed keywords

HEMATIN; HEME ARGINATE; HEME DERIVATIVE;

ACUTE INTERMITTENT PORPHYRIA; ARTICLE; DOCUMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME DEGRADATION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STEM CELL;

EID: 0031940457     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007140     Document Type: Article

References (19)

1. Waxman AD, Collins A, Tschudy DP. Oscillations of hepatic delta-amino-levulinic acid synthetase produced in vivo by heme. Biochem Biophys Res Commun 1966;22:675-683
2. Bonkovsky HL, Tschudy DP, Collins A, et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci U S A 1971;68:2725-2729
3. Fierach CA. Hematin therapy for the porphyric attack. Semin Liver Dis 1982;2:125-131
4. Pierach CA. Treatment of the acute porphyric attack. in: Mustajoki P (ed): New therapeutic approach to hepatic porphyrias. Basel, Vammalan kirjapaino Oy, 1986, pp 30-35
5. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med 1986;315:235-238
6. Dhar GJ, Bossenmaier I, Cardinal R, et al. Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand 1978;203:437-443
7. McColl KE, Moore MR, Thompson GG, Goldberg A. Treatment with haematin in acute hepatic porphyria. Q J Med 1981;50: 161-174
8. Tenhunen R, Tokola O, Linden IB. Haem arginate: a new stable haem compound. J Pharm Pharmacol 1987;39:780-786
9. Sievers G, Hakli H, Luhtala J, Tenhunen R. Optical and EPR spectroscopy studies on haem arginate, a new compound used for treatment of porphyria. Chem Biol Interact 1987;63:105-114
10. Tokola O, Linden IB, Tenhunen R. The effects of haem arginate and haematin upon the allylisopropylacetamide induced experimental porphyria in rats. Pharmacol Toxicol 1987;61:75-78
11. Mustajoki P, Tenhunen R, Tokola O, Gothoni G. Haem arginate in the treatment of acute hepatic porphyrias. Br Med J Clin Res Ed 1986;293:538-539
12. Volm L, Rasi V, Vahtera E, Tenhunen R. Heme arginate: effects on haemostasis. Blood 1988;71:625-628
13. Tokola O, Mustajoki P, Himberg JJ. Haem arginate improves hepatic oxidative metabolism in variegate porphyria. Br J Clin Pharmacol 1988;26:753-757
14. Herrick AL, McColl KE, Moore MR, et al. Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1989;1:1295-1297
15. Watson CJ, Pierach CA, Bossenmaier I, Cardinal R. Use of hematin in the acute attack of the "inducible" hepatic prophyrias. Adv Intern Med 1978;23:265-286
16. Fuchs T, Ippen H. Treatment of acute intermittent porphyria with a new protein-bound lyophilized hematin. Dtsch Med Wochenschr 1987;112:1302-1305
17. Mustajoki P. Prevention and treatment of acute porphyric attacks. Ann Clin Res 1985;17:289-291
18. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase characterization of the enzyme. J Biol Chem 1969;244: 6388-6394
19. Dover SB, Graham A, Fitzsimons E, et al Haem arginate plus tin-protoporphyrin for acute hepatic porphyria. Lancet 1991; 338:263